Textbook outcome and nomogram-guided approaches for enhancing surgical success in elderly HCC patients: Deciphering the influence of sarcopenia
Lanari J, Lupi A, Billato I, Alessandris R, Crimì F, Caregari S, Pepe A, D’Amico F, Vitale A, Quaia E, Cillo U, Gringeri E. Textbook outcome and nomogram-guided approaches for enhancing surgical success in elderly HCC patients: Deciphering the influence of sarcopenia. Updates In Surgery 2024, 76: 2645-2654. PMID: 39373845, PMCID: PMC11602817, DOI: 10.1007/s13304-024-01992-3.Peer-Reviewed Original ResearchPsoas muscle indexElderly HCC patientsOverall survivalLiver resectionSarcopenic patientsHepatocellular carcinomaTextbook outcomePostoperative complicationsHCC patientsMedian psoas muscle indexAbsence of postoperative complicationsElderly hepatocellular carcinomaInfluence of sarcopeniaHepatocellular carcinoma nodulesPreoperative CT scanAssociated with sarcopeniaHepatocellular carcinoma patientsNon-sarcopenic individualsSarcopenia's impactOncological outcomesClavien-DindoPrognostic factorsSurgical successMuscle indexPostoperative outcomesThe Italian experience on liver transplantation for unresectable peri-hilar cholangiocarcinoma: a national survey and future perspectives
Gringeri E, Furlanetto A, Billato I, Cescon M, De Carlis L, Mazzaferro V, Romagnoli R, De Simone P, Vivarelli M, Di Benedetto F, Ravaioli M, Lauterio A, Sposito C, Patrono D, Ghinolfi D, Moccheggiani F, Di Sandro S, D’Amico F, Lanari J, Gambato M, Trapani S, Bergamo F, Cardillo M, Burra P, Cillo U. The Italian experience on liver transplantation for unresectable peri-hilar cholangiocarcinoma: a national survey and future perspectives. Updates In Surgery 2024, 76: 2505-2513. PMID: 39210194, DOI: 10.1007/s13304-024-01889-1.Peer-Reviewed Original ResearchNeoadjuvant radio-chemotherapyPerihilar cholangiocarcinomaLiver transplantationGroup 1Radio-chemotherapyGroup 2Standard of care chemotherapyRisk of cancer-related deathInclusion criteriaPeri-hilar cholangiocarcinomaRecurrence-free survivalResults of LTRisk regression analysisCancer-related deathsLiver transplant centersMayo protocolNeoadjuvant regimenNeoadjuvant treatmentCare chemotherapyOverall survivalProspective studyMayo ClinicHazard ratioTransplant centersIneffective treatmentRecurrence and tumor-related death after resection of hepatocellular carcinoma in patients with metabolic syndrome
Berardi G, Cucchetti A, Sposito C, Ratti F, Nebbia M, D’Souza D, Pascual F, Dogeas E, Tohme S, Vitale A, D’Amico F, Alessandris R, Panetta V, Simonelli I, Colasanti M, Russolillo N, Moro A, Fiorentini G, Serenari M, Rotellar F, Zimitti G, Famularo S, Ivanics T, Donando F, Hoffman D, Onkendi E, Essaji Y, Giuliani T, Ben S, Caula C, Rompianesi G, Chopra A, Abu Hilal M, Sapisochin G, Torzilli G, Corvera C, Alseidi A, Helton S, Troisi R, Simo K, Conrad C, Cescon M, Cleary S, Kwon D, Ferrero A, Ettorre G, Cillo U, Geller D, Cherqui D, Serrano P, Ferrone C, Aldrighetti L, Kingham T, Mazzaferro V. Recurrence and tumor-related death after resection of hepatocellular carcinoma in patients with metabolic syndrome. JHEP Reports 2024, 6: 101075. PMID: 38961853, PMCID: PMC11220535, DOI: 10.1016/j.jhepr.2024.101075.Peer-Reviewed Original ResearchLong-term outcomes of liver resectionRecurrence-free survivalTime of recurrenceCancer-specific survivalTumor-related factorsDevelopment of hepatocellular carcinomaHepatocellular carcinomaMetabolic syndromeLong-term survivalRisk factorsOverall survivalImpact survivalResection of hepatocellular carcinomaOutcomes of liver resectionCurative intent approachPost-recurrence survivalPredictors of recurrenceHazard of recurrenceTreatment of recurrenceRisk of recurrenceTumor-related deathLong-term outcomesDesigning future trialsAssociated with deathMedian OSEx situ liver resection for intrahepatic cholangiocarcinoma: survival analysis and comparison to systemic chemotherapy
Nieddu E, Billato I, Peluso C, Furlanetto A, Lazzari S, D'Amico F, Cillo U, Gringeri E. Ex situ liver resection for intrahepatic cholangiocarcinoma: survival analysis and comparison to systemic chemotherapy. Digestive And Liver Disease 2024, 56: s42. DOI: 10.1016/j.dld.2024.01.067.Peer-Reviewed Original ResearchProgression-free survivalCA19-9 levelsEx situ liver resectionOverall survivalIntrahepatic cholangiocarcinomaEx situ surgeryStage of diseasePerformance statusSystemic chemotherapySurgical resectionLiver resectionLiver functionHigh-volume hepatobiliary centersLower stage of diseaseMedian progression-free survivalTreated with surgical resectionEvaluate long-term outcomesSurvival analysisEx situ resectionNon-parametric log-rank testTreated with chemotherapyLog-rank testLiver function testsCox regression analysisLong-term outcomesLiver resection versus radiofrequency ablation or trans-arterial chemoembolization for early-stage (BCLC A) oligo-nodular hepatocellular carcinoma: meta-analysis
Romano P, Busti M, Billato I, D’Amico F, Marchegiani G, Pelizzaro F, Vitale A, Cillo U. Liver resection versus radiofrequency ablation or trans-arterial chemoembolization for early-stage (BCLC A) oligo-nodular hepatocellular carcinoma: meta-analysis. BJS Open 2024, 8: zrad158. PMID: 38323881, PMCID: PMC10848305, DOI: 10.1093/bjsopen/zrad158.Peer-Reviewed Original ResearchConceptsBarcelona Clinic Liver CancerTrans-arterial chemoembolizationDisease-free survivalBarcelona Clinic Liver Cancer-A patientsBenefits of LRLiver resectionRadiofrequency ablationHepatocellular carcinomaOS benefitOverall survivalA patientsBarcelona Clinic Liver Cancer ABarcelona Clinic Liver Cancer stageDisease-free survival benefitRisk ratioOutcomes of LRMeta-analysisComparative cohort studyCase-control studyChina Biological Medicine DatabaseHCC patientsCohort studyPrimary outcomeNewcastle-OttawaQuality of studies